Description

Simple

An anticoagulant or "blood thinner" used as part of the emergency treatment of heart attacks.

Clinical

A monoclonal anti-glycoprotein IIb/IIIa receptor antibody used to prevent thrombosis during percutaneous coronary intervention.

Overview

Abciximab is a Fab fragment of the chimeric human-murine monoclonal antibody 7E3. Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules. It also binds to vitronectin (αvβ3) receptor found on platelets and vessel wall endothelial and smooth muscle cells.

Pharmacology

Indication

Abciximab is indicated as an adjunct to percutaneous coronary intervention for the prevention of cardiac ischemic complications in patients undergoing percutaneous coronary intervention and in patients with unstable angina not responding to conventional medical therapy when percutaneous coronary int... Read more

Pharmacodynamic

Abciximab inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules to GPIIb/IIIa receptor sites on activated platelets. A single intravenous bolus dose from 0.15 mg/kg to 0.30 mg/kg produced rapid dose-dependent inhibition of platelet... Read more

Mechanism of action

Abciximab binds to the intact platelet GPIIb/IIIa receptor, which is a member of the integrin family of adhesion receptors and the major platelet surface receptor involved in platelet aggregation. This binding is thought to involve steric hindrance and/or conformational alterations which block acces... Read more

Absorption

Information currently not available.

Protein binding

Information currently not available.

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

Following intravenous bolus administration, free plasma concentrations of Abciximab decrease rapidly with an initial half-life of less than 10 minutes and a second phase half-life of about 30 minutes, probably related to rapid binding to the platelet GPIIb/IIIa receptors.

Route of elimination

Information currently not available.

Toxicity

Information currently not available.

Adverse Effects

Contraindications

  • Regions: US
  • Patient Conditions:
      • Name: History of vasculitis
      • Drugbank Id: DBCOND0107432
  • Regions: US
  • Patient Conditions:
      • Name: Uncontrolled Hypertension
      • Drugbank Id: DBCOND0043537
  • Regions: US
  • Patient Conditions:
      • Name: Aneurysm
      • Drugbank Id: DBCOND0020220
  • Regions: US
  • Patient Conditions:
      • Name: Arterial malformation
      • Drugbank Id: DBCOND0107431
  • Regions: US
  • With Drugs:
      • Name: Dextran
      • Drugbank Id: DB09255
  • Regions: US
  • With Categories:
      • Name: Anticoagulants
      • Drugbank Id: DBCAT000007
      • Mesh Id: D000925
  • Regions: US
  • Patient Conditions:
      • Name: Bleeding diathesis
      • Drugbank Id: DBCOND0099556
  • Regions: US
  • Patient Conditions:
      • Name: History of cerebrovascular accident
      • Drugbank Id: DBCOND0107399
  • Regions: US
  • Patient Conditions:
      • Name: History of genitourinary bleeding
      • Drugbank Id: DBCOND0107428
  • Regions: US
  • Patient Conditions:
      • Name: History of gastrointestinal bleeding
      • Drugbank Id: DBCOND0107427
  • Regions: US
  • Patient Conditions:
      • Name: Intracranial Neoplasm
      • Drugbank Id: DBCOND0082428
  • Regions: US
  • Patient Conditions:
      • Name: History of trauma
      • Drugbank Id: DBCOND0107430
  • Regions: US
  • Patient Conditions:
      • Name: History of major surgery
      • Drugbank Id: DBCOND0107429
  • Regions: US
  • Patient Conditions:
      • Name: Thrombocytopenia
      • Drugbank Id: DBCOND0006608
  • Regions: US
  • Patient Conditions:
      • Name: Active internal bleeding
      • Drugbank Id: DBCOND0107389

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Abciximab
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
(1,2,6,7-3H)Testosterone
(1,2,6,7-3H)Testosterone may increase the anticoagulant activities of Abciximab.
(R)-warfarin
The risk or severity of bleeding can be increased when Abciximab is combined with (R)-warfarin.
(S)-Warfarin
The risk or severity of bleeding can be increased when Abciximab is combined with (S)-Warfarin.
1-Testosterone
1-Testosterone may increase the anticoagulant activities of Abciximab.
18-methyl-19-nortestosterone
18-methyl-19-nortestosterone may increase the anticoagulant activities of Abciximab.
3,5-Diiodotyrosine
3,5-Diiodotyrosine may increase the anticoagulant activities of Abciximab.
4-hydroxycoumarin
The risk or severity of bleeding can be increased when Abciximab is combined with 4-hydroxycoumarin.
4-Hydroxytestosterone
4-Hydroxytestosterone may increase the anticoagulant activities of Abciximab.
5beta-dihydrotestosterone
5beta-dihydrotestosterone may increase the anticoagulant activities of Abciximab.
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline
The risk or severity of bleeding and hemorrhage can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Abciximab.
Abituzumab
The risk or severity of adverse effects can be increased when Abciximab is combined with Abituzumab.
Abrilumab
The risk or severity of adverse effects can be increased when Abciximab is combined with Abrilumab.
Aceclofenac
The risk or severity of bleeding and hemorrhage can be increased when Aceclofenac is combined with Abciximab.
Acemetacin
The risk or severity of bleeding and hemorrhage can be increased when Acemetacin is combined with Abciximab.
Acenocoumarol
The risk or severity of bleeding can be increased when Abciximab is combined with Acenocoumarol.
Acetylsalicylic acid
Acetylsalicylic acid may increase the antiplatelet activities of Abciximab.
Adalimumab
The risk or severity of adverse effects can be increased when Adalimumab is combined with Abciximab.
Adecatumumab
The risk or severity of adverse effects can be increased when Abciximab is combined with Adecatumumab.
Aducanumab
The risk or severity of adverse effects can be increased when Abciximab is combined with Aducanumab.
Afelimomab
The risk or severity of adverse effects can be increased when Abciximab is combined with Afelimomab.
2 References
  1. 1 . Authors unspecified: Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med. 1994 Apr 7;330(14):956-61.PubMed: 8121459
  2. 2 . Tcheng JE, Kandzari DE, Grines CL, Cox DA, Effron MB, Garcia E, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Fahy M, Lansky AJ, Mehran R, Stone GW: Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. Circulation. 2003 Sep 16;108(11):1316-23. Epub 2003 Aug 25.PubMed: 12939213